Results 191 to 200 of about 13,918 (210)
Some of the next articles are maybe not open access.
International Journal of Radiation Oncology, Biology, Physics
PURPOSE SABR-Dual is a phase III trial with an initial phase-I safety cohort, of two-fraction stereotactic radiotherapy (SABR) with optional MRI-based focal boost, using peri-rectal spacing, for localized prostate cancer.
E. Fredman +9 more
semanticscholar +1 more source
PURPOSE SABR-Dual is a phase III trial with an initial phase-I safety cohort, of two-fraction stereotactic radiotherapy (SABR) with optional MRI-based focal boost, using peri-rectal spacing, for localized prostate cancer.
E. Fredman +9 more
semanticscholar +1 more source
Journal of Clinical Oncology
TPS489 Background: Optimal strategies for managing oligometastatic renal cell carcinoma (RCC) are unclear. While systemic therapy is the accepted standard, Stereotactic Ablative Radiation (SAbR) is a promising alternative based on retrospective and ...
R. Hannan +15 more
semanticscholar +1 more source
TPS489 Background: Optimal strategies for managing oligometastatic renal cell carcinoma (RCC) are unclear. While systemic therapy is the accepted standard, Stereotactic Ablative Radiation (SAbR) is a promising alternative based on retrospective and ...
R. Hannan +15 more
semanticscholar +1 more source
Radiotherapy and Oncology
BACKGROUND Stereotactic Ablative Body Radiotherapy (SABR) is the standard of care for medically inoperable patients with Stage I NSCLC. The adoption of SABR and its association with cancer outcomes requires characterization.
A. Ashworth +4 more
semanticscholar +1 more source
BACKGROUND Stereotactic Ablative Body Radiotherapy (SABR) is the standard of care for medically inoperable patients with Stage I NSCLC. The adoption of SABR and its association with cancer outcomes requires characterization.
A. Ashworth +4 more
semanticscholar +1 more source
SABR for Metastasis-Directed Therapy — What We’ve Learned and What’s to Come
Nature Reviews Clinical Oncology, 2020Tyler P Robin, Jeffrey R Olsen
exaly
Trials of Locoregional Therapies Inspired by SABR-COMET
Lancet, The, 2020Martijn R Meijerink +2 more
exaly
Points to Consider Regarding the SABR-COMET Trial
Lancet, The, 2020Tom Treasure, Fergus Macbeth
exaly
Points to Consider Regarding the SABR-COMET Trial – Authors' Reply
Lancet, The, 2020David A Palma +2 more
exaly

